Myasthenia Gravis

Halozyme Therapeutics announced that argenx received FDA approval for Vyvgart Hytrulo with Enhanze for subcutaneous use in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

BOSTON — Long-term treatment with Vyvgart was safe, well-tolerated and effective in reducing immunoglobulin G antibody levels and improving clinical outcomes in patients with generalized myasthenia gravis.

The American Academy of Neurology has elected Carlayne E. Jackson, MD, FAAN, a neurologist, researcher and professor of neurology and otolaryngology at the University of Texas Health Science Center at San Antonio, as its 38th president.

In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

BOSTON — Eculizumab significantly reduced disease severity and improved quality of life at 26 weeks in adolescents with refractory generalized myasthenia gravis, according to a presenter at the American Academy of Neurology annual meeting.

Rozanolixizumab improved myasthenia gravis symptoms in people with muscle-specific kinase antibody-positive disease, according to a poster presented at the 2023 MDA Clinical & Scientific Conference in Dallas.

Ravulizumab was associated with fewer clinical deterioration events in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, according to a poster at the 2023 MDA Clinical & Scientific Conference.

The FDA has given priority review to a biologic license application from UCB for rozanolixizumab, a treatment for adults with generalized myasthenia gravis, the biopharmaceutical company announced in a press release.

The FDA has accepted a new drug application for zilucoplan, an investigational treatment for generalized myasthenia gravis in adults who are acetylcholine receptor antibody positive, UCB announced in a released statement.

A single, 500 mg dose of rituximab was associated with greater probability of minimal myasthenia gravis manifestations and reduced the need for rescue medications compared with placebo, researchers reported in JAMA Neurology.